Showing 1881-1890 of 2320 results for "".
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-juvederm-voluma-xc-for-mid-face-injection-via-cannula/2460137/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older
- Ortho Dermatologics Expands Cash-Pay Prescription Program with Walgreens Agreementhttps://practicaldermatology.com/news/ortho-dermatologics-expands-cash-pay-prescription-program-with-walgreens-agreement/2460115/Ortho Dermatologics’ Cash-Pay Prescription Plan is now available at Walgreen’s stores nationwide. Under the expanded agreement, Walgreens patients will have access to the select dermatology products included in Ortho Dermatologics’ first-of-its-kind cash-pay pres
- Psoriasis Therapy Linked to Reduced Coronary Inflammationhttps://practicaldermatology.com/news/psoriasis-therapy-linked-to-reduced-coronary-inflammation/2460112/Anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat a
- Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugshttps://practicaldermatology.com/news/summer-aad-news-understanding-the-dermatologists-role-in-reducing-skin-related-side-effects-from-new-cancer-drugs/2460107/While a new wave of targeted therapies are helping patients fight cancer, they also produce side effects that can affect patients’ hair, skin and nails that can greatly impact patients’ quality of life and threaten their ability to continue treatment. “Approximat